ESTRO 2024 - Abstract Book

S2595

Clinical - Urology

ESTRO 2024

(30%) of the patients had undergone prostatectomy, and 54% had a PSA Doubling Time greater than 10 months. Eighty-one percent (81%) of the patients received rSBRT to the prostate/prostatic bed (30-36.25/5Fx), while 16% received focused rSBRT to an intraprostatic nodule (30-35 Gy/5Fx). Thirty-five percent (35%) of patients received concurrent hormonal therapy. After a median follow-up of 23.3 months, biochemical recurrence occurred in 30% of patients, and 14% developed metastatic disease. Median biochemical recurrence-free survival (BRFS) and metastasis- free survival (MFS) weren’t reached. In univariate analysis no risk factor was associated with worse BRFS or MFS. No patient experienced acute genitourinary toxicity of grade 3 or higher, and only one patient (2%) experienced late genitourinary toxicity of grade 3. There were no acute or late gastrointestinal toxicities of grade 3 or higher recorded.

Conclusion:

Reirradiation of patients with prostate cancer who have previously received radiotherapy is a valuable, effective, and safe option. This study demonstrates that salvage SBRT allows excellent disease control with acceptable toxicity. Our results are consistent with international literature.

Keywords: Prostate cancer, Reirradiation, Linear Accelerator

2961

Digital Poster

Radiation therapy of oligometastatic prostate cancers as seen by radiation oncologists

Nejla Fourati, Wafa Mnejja, Rim Trigui, Mariem Frikha, Wicem Siala, Jamel Daoud

Habib Bourguiba Hospital Faculty of Medicine University of Sfax, Radiotherapy Department, Sfax, Tunisia

Purpose/Objective:

Local radiotherapy of low-volume metastatic prostate cancers is a recommendation with a high grade since the publication of the results of the 2 randomized trials (Horrad and STAMPED) and the meta-analysis (STOPCAP). However, the modalities of this radiotherapy and the indications of metastasis-directed treatment are still controversial.

The purpose of this study was to describe radiation oncologists’ practices for modalities of radiotherapy and metastasis-directed radiotherapy in the case of low-volume metastatic prostate cancer.

Material/Methods:

An online survey with 7 questions was sent to RO.